Insider Selling: Quantum-Si (NASDAQ:QSI) Insider Sells $13,600.80 in Stock

Quantum-Si Incorporated (NASDAQ:QSI) insider John Vieceli sold 15,112 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $0.90, for a total transaction of $13,600.80. Following the sale, the insider directly owned 1,140,434 shares of the company’s stock, valued at $1,026,390.60. This represents a 1.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Quantum-Si Trading Down 0.3%

Shares of QSI opened at $0.85 on Friday. Quantum-Si Incorporated has a twelve month low of $0.69 and a twelve month high of $3.10. The firm has a market capitalization of $186.14 million, a P/E ratio of -1.68 and a beta of 3.18. The stock’s fifty day simple moving average is $0.99 and its 200 day simple moving average is $1.03.

Quantum-Si (NASDAQ:QSI) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. The company had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.30 million. Quantum-Si had a negative return on equity of 47.35% and a negative net margin of 5,605.88%. Sell-side analysts predict that Quantum-Si Incorporated will post -0.49 earnings per share for the current year.

Institutional Investors Weigh In On Quantum-Si

A number of large investors have recently modified their holdings of the stock. Invesco Ltd. lifted its position in Quantum-Si by 177.7% during the 1st quarter. Invesco Ltd. now owns 103,657 shares of the company’s stock worth $124,000 after acquiring an additional 66,336 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Quantum-Si by 23.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,552 shares of the company’s stock worth $85,000 after purchasing an additional 13,546 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Quantum-Si during the first quarter worth $4,721,000. JPMorgan Chase & Co. boosted its stake in shares of Quantum-Si by 15.6% in the second quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock valued at $131,000 after purchasing an additional 9,005 shares during the period. Finally, Rhumbline Advisers grew its holdings in Quantum-Si by 36.0% during the 2nd quarter. Rhumbline Advisers now owns 203,967 shares of the company’s stock valued at $400,000 after purchasing an additional 53,994 shares in the last quarter. Institutional investors and hedge funds own 39.90% of the company’s stock.

Analysts Set New Price Targets

QSI has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quantum-Si in a research report on Wednesday. Canaccord Genuity Group dropped their price objective on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $1.00.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.